Trial · NCT06860269
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival | At 5 years | For GRAAL-2024/B HR patients (phase 3) |
| Primary | Overall survival | At 5 years | For GRAAL-2024/B SR patients (phase 2) |
| Primary | Event-Free Survival | At 5 years | For GRAAL-2024/T patients (phase 3) |
| Primary | Overall survival | At 5 years | For GRAAPH-2024 patients (phase 3) - Phpos ALL |
| Secondary | Overall survival | At 5 years | in the T-ALL/LL cohorts |
| Secondary | Event Free Survival | At 5 years | |
| Secondary | Relapse Free Survival | At 5 years | |
| Secondary | Hematological complete response rate | At 45 days | After induction |
| Secondary | Hematological complete response rate | At 4 months | After consolidation |
| Secondary | Measurable residual disease (MRD) response level | At inclusion | (IG/TR and BCR::ABL1 markers) at diagnosis |
| Secondary | Measurable residual disease (MRD) response level - non graft patients | Up to 6 months | (IG/TR and BCR::ABL1 markers) After each treatment cycle until maintenance (4 to 5 times) |
| Secondary | Measurable residual disease (MRD) response level - graft patients | Through study completion, approximately 5 years | (IG/TR and BCR::ABL1 markers) At day 100 post-HSCT and every 3 months post HSCT for patients receiving allo-HSCT during maintenance up to 2 years |
| Secondary | Measurable residual disease (MRD) response level | Up to 5 years | (IG/TR and BCR::ABL1 markers) At relapse |
| Secondary | Early mortality | At day 30 | |
| Secondary | Early mortality | At day 60 | |
| Secondary | Early mortality | At day 90 | |
| Secondary | Cumulative incidence of relapse (CIR) | At 5 years | |
| Secondary | Cumulative incidence of non relapse mortality | At 5 years | |
| Secondary | Transplant-related mortality (TRM) | At 5 years | For graft patients |
| Secondary | Graft-versus-host-disease (GvHD) incidence | At 5 years | For graft patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06860269/registered